Drugmaker GSK has agreed to pay up to 1.15 billion US dollars (£950 million) for a US-based biopharmaceutical company which is developing rare cancer therapies.
GSK said the acquisition of IDRx will help it target a “major gap in the current standard of care” related to gastrointestinal cancers.
